{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:14:15Z","timestamp":1792854855343,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Chemicals and Fertilizers, Government of India"},{"name":"NIPER-G"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ijpharm.2015.09.014","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T19:03:11Z","timestamp":1442084591000},"page":"439-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"title":["Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach"],"prefix":"10.1016","volume":"495","author":[{"given":"Vivek","family":"Makwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Nivsarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2015.09.014_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2010.10.002","article-title":"Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting","volume":"42","author":"Alex","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0010","article-title":"Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz","author":"Avachat","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.colsurfb.2012.05.019","article-title":"Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides","volume":"100","author":"Bandyopadhyay","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.vascn.2003.11.004","article-title":"A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat","volume":"49","author":"Boyd","year":"2004","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.apt.2012.09.002","article-title":"Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles","volume":"24","author":"Burra","year":"2013","journal-title":"Adv. Powder Technol."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.colsurfb.2012.04.027","article-title":"Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system","volume":"97","author":"Chalikwar","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"4","key":"10.1016\/j.ijpharm.2015.09.014_bib0035","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejps.2004.12.006","article-title":"Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs","volume":"24","author":"Dahan","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2011.08.009","article-title":"Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival","volume":"156","author":"Dane","year":"2011","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ijpharm.2015.09.014_bib0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1208\/s12249-010-9385-0","article-title":"Preparation and bioavailability assessment of SMEDDS containing valsartan","volume":"11","author":"Dixit","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.01.012","article-title":"The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins","volume":"333","author":"Gershkovich","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0055","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.addr.2009.11.018","article-title":"Non-polymeric nano-carriers in HIV\/AIDS drug delivery and targeting","volume":"62","author":"Gupta","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0060","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1023\/A:1020311127328","article-title":"Structured triglycerides vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats","volume":"19","author":"Holm","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0065","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1211\/0022357044959","article-title":"Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs","volume":"56","author":"Hu","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/10611860903338462","article-title":"Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system","volume":"18","author":"Kalam","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0075","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1023\/A:1025718513246","article-title":"Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs","volume":"20","author":"Khoo","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2006.11.004","article-title":"Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics","volume":"335","author":"Kumar","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0085","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.colsurfa.2007.11.011","article-title":"Effect of poly(ethylene glycol) stearate on the phase behaviour of monocaprate \/Tween80 \/ water system and characterization of poly(ethylene glycol) stearate-modified solid lipid nanoparticles","volume":"317","author":"Li","year":"2008","journal-title":"Colloids Surf. A"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2005.06.006","article-title":"Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration","volume":"107","author":"Manjunath","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0168-3659(94)90253-4","article-title":"Phase transition temperature reduction and glass transformation in dehydroprotected lyophilized liposomes","volume":"31","author":"Mobley","year":"1994","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejps.2012.10.022","article-title":"Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique","volume":"48","author":"Negi","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0110","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0928-0987(02)00051-9","article-title":"Lipid-based formulations for intestinal lymphatic delivery","volume":"15","author":"O\u2019Driscoll","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1006\/mvre.1994.1025","article-title":"Limits to steady state lymph flow rates derived from plasma-to-tissue uptake measurements","volume":"47","author":"Renekin","year":"1994","journal-title":"Microvasc. Res."},{"issue":"2","key":"10.1016\/j.ijpharm.2015.09.014_bib0120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1208\/s12249-010-9404-1","article-title":"Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir","volume":"11","author":"Sinha","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/02652040701817762","article-title":"Physicochemical characterization and in vitro release studies of ascorbylpalmitate-loaded semi-solid nanostructured lipid carriers (NLC gels)","volume":"25","author":"Teeranachaideekul","year":"2008","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0130","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","article-title":"Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update","volume":"60","author":"Trevaskis","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2012.01.001","article-title":"Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration","volume":"95","author":"Venishetty","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"4","key":"10.1016\/j.ijpharm.2015.09.014_bib0140","doi-asserted-by":"crossref","DOI":"10.1208\/pt0804083","article-title":"Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles","volume":"8","author":"Vivek","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2015.09.014_bib0145","unstructured":"Westesen, K., 2000. Particles with Modified Physico-Chemical Properties, their Preparation and Uses, US Patent No. 6197349."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851731530212X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851731530212X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T12:55:19Z","timestamp":1537361719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851731530212X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S037851731530212X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.09.014","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}